Source link : https://newshealth.biz/health-news/tirzepatide-matches-competitors-cardioprotective-benefits-for-diabetics/
(MedPage Today) — The dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) was just as cardioprotective as the GLP-1 drug dulaglutide (Trulicity) in patients with type 2 diabetes and atherosclerotic cardiovascular disease, a large… Source link : https://www.medpagetoday.com/cardiology/prevention/119074 Author : Publish date : 2025-12-17 22:47:00 Copyright for syndicated content belongs to the linked Source.
The post Tirzepatide Matches Competitor’s Cardioprotective Benefits for Diabetics first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-17 22:47:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8